---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003044"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:01:48.077190+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q1 net loss $50.3M includes $48M goodwill impairment; guides Q2 revenue $18-20M

## Summary
- Revenue $21.8M vs $24.5M YoY (-11%); net loss $(50.3)M vs $(4.7)M, including $48.0M goodwill impairment.
- Gross margin 56.0% vs 60.3% YoY; Adjusted EBITDA $0.8M vs $1.6M YoY.
- Q2 2025 guidance: revenue $18M-$20M, gross margin 55%-57%.
- CEO cites NIH funding uncertainty, tariff impact on China sales; cost savings ~$1M/qtr starting Q2.

## SEC filing metadata
- accession: 0001171843-25-003044
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184325003044/0001171843-25-003044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184325003044/f8k_051225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003044
- JSON: https://secwatch.observer/filing/0001171843-25-003044.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.